TESARO Inc  

(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for Timothy Pearson�
29.01
+1.18 (4.24%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.63 - 29.19
52 week 22.15 - 47.89
Open 27.99
Vol / Avg. 150,418.00/337,732.00
Mkt cap 1.05B
P/E     -
Div/yield     -
EPS -3.69
Shares 36.04M
Beta     -
Inst. own 99%
Jul 24, 2014
Q2 2014 TESARO Inc Earnings Call
Jul 24, 2014
Q2 2014 TESARO Inc Earnings Release
Jun 1, 2014
TESARO Inc ASCO Investor Briefing
May 21, 2014
TESARO Inc at UBS Global Healthcare Conference
May 16, 2014
TESARO Inc Annual Shareholder Meeting
May 7, 2014
TESARO Inc at Deutsche Bank Healthcare Conference
May 6, 2014
TESARO Inc at Mizuho Securities USA Healthcare Corporate Access Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -124.17% -70.25%
Return on average equity -135.99% -77.35%
Employees 62 -
CDP Score - -

Address

SUITE 3300, 1000 WINTER STREET
WALTHAM, MA 02451
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 51
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Lawrence M. Alleva Independent Director
Age: 64
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Earl M. Collier Jr., Esq. Independent Director
Age: 65
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Beth C. Seidenberg M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters